Do analysts rate MRAI or PIII?

P3 Health Partners has a consensus price target of $14.00, suggesting a potential upside of 23.13%. Given P3 Health Partners' stronger consensus rating and higher possible upside, analysts plainly believe P3 Health Partners is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 P3 Health Partners 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is MRAI or PIII more profitable?

P3 Health Partners has a net margin of -8.57% compared to Marpai's net margin of -85.70%. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% P3 Health Partners -8.57% N/A -19.99%

Do analysts recommend SERA or MRAI?

Sera Prognostics currently has a consensus price target of $5.50, indicating a potential upside of 175.00%. Given Sera Prognostics' stronger consensus rating and higher possible upside, equities analysts plainly believe Sera Prognostics is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sera Prognostics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, SERA or MRAI?

Marpai has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sera Prognostics $80K 979.00 -$31.93M -$0.65 N/A Marpai $34.87M 0.54 -$28.75M -$0.87 N/A

Is SERA or MRAI more profitable?

Marpai has a net margin of -85.70% compared to Sera Prognostics' net margin of -56,385.97%. Marpai's return on equity of 0.00% beat Sera Prognostics' return on equity. Company Net Margins Return on Equity Return on Assets Sera Prognostics -56,385.97% -41.02% -30.95% Marpai -85.70% N/A -100.23%

Do analysts rate NAKA or MRAI?

KindlyMD currently has a consensus target price of $30.00, indicating a potential upside of 677.20%. Given KindlyMD's stronger consensus rating and higher possible upside, equities research analysts plainly believe KindlyMD is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KindlyMD 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, NAKA or MRAI?

Marpai has higher revenue and earnings than KindlyMD. Marpai is trading at a lower price-to-earnings ratio than KindlyMD, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio KindlyMD $1.82M 36.90 -$52.23M -$43.20 N/A Marpai $34.87M 0.54 -$28.75M -$0.87 N/A

Is NAKA or MRAI more profitable?

Marpai has a net margin of -85.70% compared to KindlyMD's net margin of -7,397.12%. Marpai's return on equity of 0.00% beat KindlyMD's return on equity. Company Net Margins Return on Equity Return on Assets KindlyMD -7,397.12% -81.32% -54.17% Marpai -85.70% N/A -100.23%

Do analysts recommend DCGO or MRAI?

DocGo presently has a consensus target price of $2.38, indicating a potential upside of 327.47%. Given DocGo's stronger consensus rating and higher probable upside, equities analysts plainly believe DocGo is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DocGo 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, DCGO or MRAI?

Marpai has lower revenue, but higher earnings than DocGo. Marpai is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $322.20M 0.17 -$182.40M -$1.91 N/A Marpai $34.87M 0.54 -$28.75M -$0.87 N/A

Is DCGO or MRAI more profitable?

DocGo has a net margin of -62.23% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat DocGo's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -62.23% -44.09% -29.14% Marpai -85.70% N/A -100.23%

Do analysts prefer MRAI or EUDA?

EUDA Health has a consensus price target of $55.00, indicating a potential upside of 296.25%. Given EUDA Health's stronger consensus rating and higher possible upside, analysts clearly believe EUDA Health is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 EUDA Health 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is MRAI or EUDA more profitable?

EUDA Health has a net margin of 0.00% compared to Marpai's net margin of -85.70%. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% EUDA Health N/A N/A N/A

Marpai (MRAI) Competitors

$0.70 -0.02 (-2.50%)

As of 07/2/2026 03:59 PM Eastern

Compare

MRAI vs. PIII, SERA, NAKA, DCGO, and EUDA

Should you buy Marpai stock or one of its competitors? MarketBeat compares Marpai with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Marpai include P3 Health Partners (PIII), Sera Prognostics (SERA), KindlyMD (NAKA), DocGo (DCGO), and EUDA Health (EUDA). These companies are all part of the "healthcare" industry.

How does Marpai compare to P3 Health Partners?

Marpai (NASDAQ:MRAI) and P3 Health Partners (NASDAQ:PIII) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

P3 Health Partners has a net margin of -8.57% compared to Marpai's net margin of -85.70%.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
P3 Health Partners	-8.57%	N/A	-19.99%

Marpai has a beta of 4.92, meaning that its share price is 392% more volatile than the broader market. Comparatively, P3 Health Partners has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market.

In the previous week, P3 Health Partners had 2 more articles in the media than Marpai. MarketBeat recorded 2 mentions for P3 Health Partners and 0 mentions for Marpai. P3 Health Partners' average media sentiment score of 0.79 beat Marpai's score of 0.00 indicating that P3 Health Partners is being referred to more favorably in the news media.

Company	Overall Sentiment
Marpai	Neutral
P3 Health Partners	Positive

49.8% of Marpai shares are owned by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are owned by institutional investors. 46.1% of Marpai shares are owned by company insiders. Comparatively, 10.9% of P3 Health Partners shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Marpai has higher earnings, but lower revenue than P3 Health Partners. Marpai is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	0.54	-$28.75M	-$0.87	N/A
P3 Health Partners	$1.46B	0.06	-$147.95M	-$38.60	N/A

P3 Health Partners has a consensus price target of $14.00, suggesting a potential upside of 23.13%. Given P3 Health Partners' stronger consensus rating and higher possible upside, analysts plainly believe P3 Health Partners is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

P3 Health Partners beats Marpai on 8 of the 15 factors compared between the two stocks.

How does Marpai compare to Sera Prognostics?

Sera Prognostics (NASDAQ:SERA) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Sera Prognostics currently has a consensus price target of $5.50, indicating a potential upside of 175.00%. Given Sera Prognostics' stronger consensus rating and higher possible upside, equities analysts plainly believe Sera Prognostics is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Marpai has a net margin of -85.70% compared to Sera Prognostics' net margin of -56,385.97%. Marpai's return on equity of 0.00% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-56,385.97%	-41.02%	-30.95%
Marpai	-85.70%	N/A	-100.23%

In the previous week, Sera Prognostics had 2 more articles in the media than Marpai. MarketBeat recorded 2 mentions for Sera Prognostics and 0 mentions for Marpai. Sera Prognostics' average media sentiment score of 0.00 equaled Marpai'saverage media sentiment score.

Company	Overall Sentiment
Sera Prognostics	Neutral
Marpai	Neutral

Marpai has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	979.00	-$31.93M	-$0.65	N/A
Marpai	$34.87M	0.54	-$28.75M	-$0.87	N/A

54.6% of Sera Prognostics shares are held by institutional investors. Comparatively, 49.8% of Marpai shares are held by institutional investors. 11.3% of Sera Prognostics shares are held by company insiders. Comparatively, 46.1% of Marpai shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Sera Prognostics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Marpai has a beta of 4.92, indicating that its stock price is 392% more volatile than the broader market.

Summary

Sera Prognostics beats Marpai on 9 of the 16 factors compared between the two stocks.

How does Marpai compare to KindlyMD?

KindlyMD (NASDAQ:NAKA) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

Marpai has a net margin of -85.70% compared to KindlyMD's net margin of -7,397.12%. Marpai's return on equity of 0.00% beat KindlyMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KindlyMD	-7,397.12%	-81.32%	-54.17%
Marpai	-85.70%	N/A	-100.23%

49.8% of Marpai shares are held by institutional investors. 24.5% of KindlyMD shares are held by company insiders. Comparatively, 46.1% of Marpai shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Marpai has higher revenue and earnings than KindlyMD. Marpai is trading at a lower price-to-earnings ratio than KindlyMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KindlyMD	$1.82M	36.90	-$52.23M	-$43.20	N/A
Marpai	$34.87M	0.54	-$28.75M	-$0.87	N/A

KindlyMD has a beta of 16.05, suggesting that its stock price is 1,505% more volatile than the broader market. Comparatively, Marpai has a beta of 4.92, suggesting that its stock price is 392% more volatile than the broader market.

KindlyMD currently has a consensus target price of $30.00, indicating a potential upside of 677.20%. Given KindlyMD's stronger consensus rating and higher possible upside, equities research analysts plainly believe KindlyMD is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KindlyMD	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, KindlyMD had 1 more articles in the media than Marpai. MarketBeat recorded 1 mentions for KindlyMD and 0 mentions for Marpai. KindlyMD's average media sentiment score of 0.00 equaled Marpai'saverage media sentiment score.

Company	Overall Sentiment
KindlyMD	Neutral
Marpai	Neutral

Summary

KindlyMD beats Marpai on 8 of the 15 factors compared between the two stocks.

How does Marpai compare to DocGo?

DocGo (NASDAQ:DCGO) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

In the previous week, DocGo had 2 more articles in the media than Marpai. MarketBeat recorded 2 mentions for DocGo and 0 mentions for Marpai. DocGo's average media sentiment score of 0.40 beat Marpai's score of 0.00 indicating that DocGo is being referred to more favorably in the media.

Company	Overall Sentiment
DocGo	Neutral
Marpai	Neutral

DocGo has a net margin of -62.23% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-62.23%	-44.09%	-29.14%
Marpai	-85.70%	N/A	-100.23%

Marpai has lower revenue, but higher earnings than DocGo. Marpai is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.17	-$182.40M	-$1.91	N/A
Marpai	$34.87M	0.54	-$28.75M	-$0.87	N/A

DocGo presently has a consensus target price of $2.38, indicating a potential upside of 327.47%. Given DocGo's stronger consensus rating and higher probable upside, equities analysts plainly believe DocGo is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

56.4% of DocGo shares are owned by institutional investors. Comparatively, 49.8% of Marpai shares are owned by institutional investors. 3.8% of DocGo shares are owned by company insiders. Comparatively, 46.1% of Marpai shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

DocGo has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market. Comparatively, Marpai has a beta of 4.92, indicating that its share price is 392% more volatile than the broader market.

Summary

DocGo beats Marpai on 9 of the 16 factors compared between the two stocks.

How does Marpai compare to EUDA Health?

Marpai (NASDAQ:MRAI) and EUDA Health (NASDAQ:EUDA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

EUDA Health has a consensus price target of $55.00, indicating a potential upside of 296.25%. Given EUDA Health's stronger consensus rating and higher possible upside, analysts clearly believe EUDA Health is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
EUDA Health	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Marpai has a beta of 4.92, suggesting that its share price is 392% more volatile than the broader market. Comparatively, EUDA Health has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

In the previous week, Marpai's average media sentiment score of 0.00 equaled EUDA Health'saverage media sentiment score.

Company	Overall Sentiment
Marpai	Neutral
EUDA Health	Neutral

EUDA Health has a net margin of 0.00% compared to Marpai's net margin of -85.70%.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
EUDA Health	N/A	N/A	N/A

49.8% of Marpai shares are owned by institutional investors. Comparatively, 4.4% of EUDA Health shares are owned by institutional investors. 46.1% of Marpai shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

EUDA Health has lower revenue, but higher earnings than Marpai. EUDA Health is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	0.54	-$28.75M	-$0.87	N/A
EUDA Health	$6.82M	6.09	-$2.77M	-$2.40	N/A

Summary

EUDA Health beats Marpai on 7 of the 13 factors compared between the two stocks.

Get Marpai News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRAI vs. The Competition

Export

Metric	Marpai	health & allied services, not elsewhere classified Industry	Business Sector	NASDAQ Exchange
Market Cap	$19.16M	$83.45M	$6.98B	$12.47B
Dividend Yield	N/A	N/A	3.12%	6.51%
P/E Ratio	-0.27	0.74	29.83	24.69
Price / Sales	0.54	0.31	368.85	98.64
Price / Cash	N/A	4.19	23.78	57.09
Price / Book	-0.41	0.15	5.90	6.46
Net Income	-$28.75M	$25.15M	$205.38M	$337.01M
7 Day Performance	-1.83%	-3.88%	1.90%	1.69%
1 Month Performance	25.36%	8.52%	1.80%	0.67%
1 Year Performance	-48.00%	-38.94%	18.92%	23.93%

Marpai Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRAI Marpai	N/A	$0.70 -2.5%	N/A	-48.0%	$19.16M	$34.87M	N/A	150	Gap Up
PIII P3 Health Partners	3.066 of 5 stars	$11.07 +2.5%	$14.00 +26.5%	+78.6%	$78.25M	$1.46B	N/A	500	News Coverage Analyst Upgrade Short Interest Decrease Gap Down
SERA Sera Prognostics	2.8672 of 5 stars	$2.03 +11.5%	$5.50 +170.9%	-19.8%	$71.27M	$80K	N/A	120	News Coverage
NAKA KindlyMD	3.4599 of 5 stars	$4.01 +1.5%	$30.00 +648.1%	-99.2%	$68.74M	$1.82M	N/A	N/A	Gap Up
DCGO DocGo	2.9661 of 5 stars	$0.55 +6.0%	$2.38 +334.2%	-64.9%	$50.97M	$322.20M	N/A	3,568	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRAI) was last updated on 7/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Marpai (MRAI) Competitors

MRAI vs. PIII, SERA, NAKA, DCGO, and EUDA

How does Marpai compare to P3 Health Partners?

Summary

How does Marpai compare to Sera Prognostics?

Summary

How does Marpai compare to KindlyMD?

Summary

How does Marpai compare to DocGo?

Summary

How does Marpai compare to EUDA Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRAI vs. The Competition

Marpai Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Marpai (MRAI) Competitors

MRAI vs. PIII, SERA, NAKA, DCGO, and EUDA

How does Marpai compare to P3 Health Partners?

Is MRAI or PIII more profitable?

Which has more risk & volatility, MRAI or PIII?

Does the media refer more to MRAI or PIII?

Do institutionals & insiders hold more shares of MRAI or PIII?

Which has stronger valuation & earnings, MRAI or PIII?

Do analysts rate MRAI or PIII?

Summary

How does Marpai compare to Sera Prognostics?

Do analysts recommend SERA or MRAI?

Is SERA or MRAI more profitable?

Does the media prefer SERA or MRAI?

Which has higher valuation & earnings, SERA or MRAI?

Do insiders and institutionals believe in SERA or MRAI?

Which has more risk and volatility, SERA or MRAI?

Summary

How does Marpai compare to KindlyMD?

Is NAKA or MRAI more profitable?

Do institutionals & insiders believe in NAKA or MRAI?

Which has stronger earnings and valuation, NAKA or MRAI?

Which has more risk & volatility, NAKA or MRAI?

Do analysts rate NAKA or MRAI?

Does the media prefer NAKA or MRAI?

Summary

How does Marpai compare to DocGo?

Does the media favor DCGO or MRAI?

Is DCGO or MRAI more profitable?

Which has preferable earnings and valuation, DCGO or MRAI?

Do analysts recommend DCGO or MRAI?

Do institutionals and insiders have more ownership in DCGO or MRAI?

Which has more volatility & risk, DCGO or MRAI?

Summary

How does Marpai compare to EUDA Health?

Do analysts prefer MRAI or EUDA?

Which has more risk and volatility, MRAI or EUDA?

Does the media favor MRAI or EUDA?

Is MRAI or EUDA more profitable?

Do institutionals & insiders have more ownership in MRAI or EUDA?

Which has better valuation and earnings, MRAI or EUDA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRAI vs. The Competition

Marpai Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools